Background
Fever control may improve vascular tone and decrease oxygen consumption; however, fever may help combat infection.
Methods
Objective: To determine whether fever control by external cooling diminishes vasopressor requirements in septic shock. Design: A multicenter randomized controlled trial. Setting: Seven ICUs in France. Subjects: Febrile patients with septic shock requiring vasopressors, mechanical ventilation, and sedation. Intervention: Patients were randomly allocated to exter nal cooling to achieve normothermia (36.5 to 37.8°C) for 48 hours. Outcomes: Th e primary outcome was the number of patients with a 50% decrease in baseline vasopressor dose after 48 hours. Secondary outcomes were the numbers of patients with a 50% baseline vasopressor dose decrease after 2, 12, 24, and 36 hours, the percentage of patients requiring a vasopressor dose increase within 48 hours of baseline, the percentage of patients with shock reversal in the ICU, the change in Sequential Organ Failure Assessment score (ΔSOFA) versus baseline, and all-cause mortality on day 14 and at ICU and hospital discharge.
Results
Th ere were 200 patients randomized, 101 to the cooling group and 99 to the no-cooling group. Th e percentage of patients with a 50% vasopressor dose decrease versus baseline was not signifi cantly diff erent at 48 hours of treatment (72% vs. 61%; absolute diff erence, 11%; 95% confi dence interval (CI), -23 to 2; P = 0.4), although it was at 12 hours (54% vs. 20%; absolute diff erence, 34%; 95% CI, -46 to -21; P <0.001). External cooling signifi cantly reduced the number of patients needing a vasopressor dose increase (34% vs. 52%; absolute diff erence, -18%; 95% CI, -4 to -31%; P = 0.011) and signifi cantly increased the shock reversal during the study period (86% vs. 73%; absolute diff erence, 13%; 95% CI, 2 to 25%; P = 0.021). Day 14 mortality was signifi cantly lower in the cooling group (19% vs. 34%; absolute diff erence, -16%; 95% CI, -28 to -4; P = 0.013), but mortality was not diff erent at ICU and hospital discharge.
Conclusions
Fever control using external cooling was safe, and decreased vasopressor requirements and early mortality in septic shock.
Commentary
Septic shock, defi ned as sepsis and hypotension refractory to fl uid resuscitation, is the leading cause of death in noncoronary ICUs, and is associated with mortality of 40 to 60% [1] [2] [3] . Initiated by an infection, severe sepsis and septic shock may be due to a dysregulated infl ammatory response [4] .
Fever is defi ned as core temperature ≥38.3°C [5, 6] . Approxi mately 90% of patients with severe sepsis are febrile [7] . During sepsis, fever occurs in response to endogenous (IL-1β, TNFα, IFNγ, prostaglandin E 2 ) and/ or exogenous pyrogenic substances that reset the thermo regulatory center. Fever is an important adaptive response to infection [8] . Although it has benefi cial and detrimental eff ects, the net role of fever in the pathophysiology of septic shock is unclear.
Benefi cial eff ects include decreased bacterial and viral growth due to denaturation of essential enzymes, such as viral polymerase and/or promoter complexes [9, 10] . Fever also alters the immune response. Heat shock proteins induced by fever have direct cytoprotective eff ects and downregulate NF-κB, subsequently modifying the expression of infl ammatory mediators and limiting the collateral damage of infl ammation. Fever also enhances cytotoxic activity of eff ector cells, such as neutrophils and macrophages, leading to more rapid pathogen clearance [11] . Detrimental eff ects of fever include increased oxygen consumption. In patients with septic shock there is limited ability to meet the increased metabolic demands because of disturbances in cardiac and pulmonary function [12] . In febrile critically ill patients, the reduction of fever from 39 to 37°C led to a decrease in oxygen consumption and unloaded the cardio pulmonary system, which favored resuscitation of patients with limited oxygen delivery [13] .
Pharmacologic approaches have been tested to control fever in patients with infection. For instance, ibuprofen has been studied in a randomized controlled trial in humans and no improvement of survival was found, even though the drug did have a salutary eff ect on core temperature and metabolic rate [14] . External cooling is another option to control fever without exposing the patient to the potential adverse eff ects of antipyretic drugs, such as increased risk of bleeding and hepatic and renal toxicity [12] .
Th e current study is a multicenter randomized controlled trial, set to determine the eff ect of external cooling on vascular tone. Th e primary endpoint was 50% reduction in baseline vasopressor dose at 48 hours, while the secondary endpoints were 50% reduction in baseline vaso pressor at various time points over 48 hours, vasopressor dose increase, shock reversal, change in Sequential Organ Failure Assessment score, and mortality on day 14 and at ICU and hospital discharge.
Th e hemodynamic improvement was evident through shock reversal, smaller change in Sequential Organ Failure Assessment score, and fewer cases of renal replacement therapy initiation in the cooling arm. Additionally, external cooling reduced day 14 mortality but did not change ICU or hospital mortality. Th e benefi cial eff ect of cooling was more pronounced in the subgroup receiving the highest vasopressor dose.
Th e study has multiple strengths. Patients were enrolled on average within 1 hour from ICU admission and cooling was initiated promptly. Vasopressor manage ment was protocolized. Th e study reported a good safety profi le for external cooling, considering the patients were sedated and on mechanical ventilation and considering neuromuscular blockade was used in a large proportion of the study population. Th e study has some limitations. First, there was no mechanistic explanation (for example, reduced oxygen consumption, improved vascular tone, or diff erences in infl ammatory response) for the benefi cial eff ect of fever control. Second, the eff ect of fever reduction on hemo dynamic stability was temporary, since there was no diff erence in the number of patients with 50% reduction in vasopressor use at 48 hours. Also, no diff erence in mortality at ICU or hospital discharge was observed. Although most patients were on adequate antimicrobial coverage by the time of cooling, there was a trend toward an increased incidence of nosocomial infections on day 14 in the cooling group.
Recommendation
Th e results of this study suggest no harm in external cooling to control fever in patients with septic shock. A large multicenter randomized control trial is required to determine the effi cacy and to shed insights on the underlying mechanistic eff ect of this intervention before it can be used routinely for septic shock patients.
